Discounted Cash Flow (DCF) Analysis Unlevered

Aerie Pharmaceuticals, Inc. (AERI)

$11.57

+0.48 (+4.33%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 11.57 | undervalue

Operating Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 11.57
Beta 0.350
Diluted Shares Outstanding 46.34
Cost of Debt
Tax Rate -0.80
After-tax Cost of Debt 11.09%
Risk-Free Rate
Market Risk Premium
Cost of Equity 4.502
Total Debt 260.64
Total Equity 536.11
Total Capital 796.75
Debt Weighting 32.71
Equity Weighting 67.29
Wacc

Build Up Free Cash

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 1.20%-0.00%0.05%-2.95%-0.80%-0.50%-0.50%-0.50%-0.50%-0.50%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -15.97-31.31-9.96-3.10-3.29-----
UFCF ----------
WACC
PV UFCF -----
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 6.66
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt 223.46
Equity Value -
Shares Outstanding 46.34
Equity Value Per Share -